Comparison of 3D Conformal Proton Therapy, Intensity-Modulated Proton Therapy, and Intensity-Modulated Photon Therapy for Retroperitoneal Sarcoma.
Journal
Sarcoma
ISSN: 1357-714X
Titre abrégé: Sarcoma
Pays: Egypt
ID NLM: 9709257
Informations de publication
Date de publication:
2022
2022
Historique:
received:
27
02
2021
revised:
11
12
2021
accepted:
14
02
2022
entrez:
29
3
2022
pubmed:
30
3
2022
medline:
30
3
2022
Statut:
epublish
Résumé
External beam radiation therapy (RT) for retroperitoneal sarcoma often requires treatment of large target volumes close to critical normal tissues. Radiation may be limited by adjacent organs at risk (OAR). Intensity-modulated radiation therapy has been shown to improve target coverage and reduce doses to OAR. To compare target coverage and dose to OAR with 3D conformal proton therapy (3D CPT), intensity-modulated proton therapy (IMPT), and intensity-modulated photon therapy (IMXT). We performed a comparative study of treatment plans with 3D CPT, IMPT, and IMXT for ten patients with retroperitoneal sarcomas. RT was delivered to 50.4 Gy to the clinical target volume (CTV), the structures considered at risk for microscopic disease. CTVs ranged from 74 to 357 cc (mean 188 cc). Dose conformity was improved with IMPT, while 3D CPT provided better dose homogeneity. Mean dose to the liver, small bowel, and stomach was reduced with IMPT compared with 3D CPT or IMXT. IMPT, 3D CPT, and IMXT provide excellent target coverage for retroperitoneal sarcomas. OAR dose is lower with IMPT and 3D CPT, and IMPT achieves the closest conformity. These techniques offer the opportunity for further dose escalation to areas with positive margins.
Sections du résumé
Background
UNASSIGNED
External beam radiation therapy (RT) for retroperitoneal sarcoma often requires treatment of large target volumes close to critical normal tissues. Radiation may be limited by adjacent organs at risk (OAR). Intensity-modulated radiation therapy has been shown to improve target coverage and reduce doses to OAR.
Objectives
UNASSIGNED
To compare target coverage and dose to OAR with 3D conformal proton therapy (3D CPT), intensity-modulated proton therapy (IMPT), and intensity-modulated photon therapy (IMXT).
Methods
UNASSIGNED
We performed a comparative study of treatment plans with 3D CPT, IMPT, and IMXT for ten patients with retroperitoneal sarcomas. RT was delivered to 50.4 Gy to the clinical target volume (CTV), the structures considered at risk for microscopic disease.
Results
UNASSIGNED
CTVs ranged from 74 to 357 cc (mean 188 cc). Dose conformity was improved with IMPT, while 3D CPT provided better dose homogeneity. Mean dose to the liver, small bowel, and stomach was reduced with IMPT compared with 3D CPT or IMXT.
Conclusions
UNASSIGNED
IMPT, 3D CPT, and IMXT provide excellent target coverage for retroperitoneal sarcomas. OAR dose is lower with IMPT and 3D CPT, and IMPT achieves the closest conformity. These techniques offer the opportunity for further dose escalation to areas with positive margins.
Identifiants
pubmed: 35345672
doi: 10.1155/2022/5540615
pmc: PMC8957461
doi:
Types de publication
Journal Article
Langues
eng
Pagination
5540615Informations de copyright
Copyright © 2022 Christine Chung et al.
Déclaration de conflit d'intérêts
The authors declare that they have no conflicts of interest.
Références
Int J Radiat Oncol Biol Phys. 2007 Jan 1;67(1):164-70
pubmed: 17084556
Int J Radiat Oncol Biol Phys. 1994 Jul 30;29(5):1005-10
pubmed: 8083069
J Clin Oncol. 1997 Aug;15(8):2832-9
pubmed: 9256126
CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49
pubmed: 19474385
Ann Surg Oncol. 2010 Jun;17(6):1515-29
pubmed: 20151216
Am J Clin Oncol. 2005 Jun;28(3):310-6
pubmed: 15923806
Ann Surg. 1998 Sep;228(3):355-65
pubmed: 9742918
Ann Surg. 2015 Jul;262(1):156-62
pubmed: 26061213
J Clin Oncol. 2003 Aug 15;21(16):3092-7
pubmed: 12915599
Int J Radiat Oncol Biol Phys. 2015 Jul 1;92(3):602-12
pubmed: 26068493
Adv Radiat Oncol. 2017 Jan 04;2(1):85-93
pubmed: 28740917
Cancer. 2006 Apr 1;106(7):1610-6
pubmed: 16518798
Int J Radiat Oncol Biol Phys. 2012 Aug 1;83(5):1549-57
pubmed: 22270176
Ann Surg. 2016 May;263(5):1002-9
pubmed: 26727100
Sarcoma. 2003;7(3-4):137-48
pubmed: 18521378
Cancer. 2006 Jul 15;107(2):371-9
pubmed: 16752414
Ann Surg Oncol. 2006 Apr;13(4):508-17
pubmed: 16491338
Lancet Oncol. 2020 Oct;21(10):1366-1377
pubmed: 32941794
Ann Surg Oncol. 1996 Mar;3(2):150-8
pubmed: 8646515
Pract Radiat Oncol. 2016 Sep-Oct;6(5):360-366
pubmed: 27009922
Cancer. 2001 Jul 15;92(2):359-68
pubmed: 11466691